Market capitalization | $619.69m |
Enterprise Value | $441.39m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.39 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-189.21m |
Free Cash Flow (TTM) Free Cash Flow | $-152.02m |
Cash position | $238.43m |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
9 Analysts have issued a Scholar Rock Holding Corp. forecast:
9 Analysts have issued a Scholar Rock Holding Corp. forecast:
Mar '24 |
+/-
%
|
||
Net Profit | -57 -57 |
44%
44%
|
|
Depreciation and Amortization | 0.60 0.60 |
76%
76%
|
|
Stock Compensation | 8.16 8.16 |
32%
32%
|
|
Operating Cash Flow | -50 -50 |
21%
21%
|
|
Investments | 0.02 0.02 |
33%
33%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -50 -50 |
21%
21%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The company offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Jay Backstrom |
Employees | 150 |
Founded | 2012 |
Website | www.scholarrock.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.